Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

ABSTRACT:

SUBMITTER: Panse J 

PROVIDER: S-EPMC12283465 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature